Structural and functional analysis of TREM2 interactions with amyloid beta reveal molecular mechanisms that mediate phagocytosis of oligomeric amyloid beta

Jessica A Greven,Omar Osario,Jay C Nix,Jennifer Alexander-Brett,Thomas J Brett

DOI: https://doi.org/10.1101/2024.05.23.595586

2024-05-25

Abstract:The TREM2 receptor is expressed on microglia in the brain, where it plays critical roles regulating microglia function. TREM2 engages a number of ligands involved in Alzheimer's disease, and consequent signaling triggers phagocytosis, activation, survival, and proliferation. TREM2 has emerged as a drug target for AD, however very little is known regarding the structural basis for TREM2 microglial functions. Here we investigated the engagement of oligomeric amyloid beta (oAb42) with TREM2. Using familial variants, we show that mutations in the N-terminal portion of Ab, notably residues H6 and D7, disrupt binding to TREM2. We then co-crystallized TREM2 with Ab(1-8) peptide and determined the high-resolution crystal structure. The structure revealed the peptide binds to the hydrophobic site of TREM2, closest to CDR1. Mutational and binding studies by BLI confirmed that mutations to the hydrophobic site ablate binding to oAb42. Finally, we show that these interactions are critical to triggering phagocytosis of oAb42, as oAb42 variants H6R and D7N are not phagocytosed. Altogether, these data indicate that TREM2 engages oAb42 using the hydrophobic site on TREM2, and the N-terminal portion of Ab, and that this interaction is critical to trigger signaling and phagocytosis.

Biophysics

What problem does this paper attempt to address?

The paper primarily explores the molecular mechanisms of the interaction between the triggering receptor expressed on myeloid cells 2 (TREM2) and amyloid beta (Aβ) oligomers, particularly their role in the pathology of Alzheimer's disease (AD). The study reveals how TREM2 recognizes and mediates the phagocytosis of Aβ oligomers, which is crucial for understanding the function of microglial cells and the management of Aβ plaques in AD. Specifically, the paper provides a detailed analysis of the binding between TREM2 and Aβ oligomers through biophysical and structural biology approaches, identifying the most critical parts of the TREM2 surface and Aβ peptide regions for this interaction. The research found that TREM2 primarily interacts with the N-terminal part of Aβ, especially at histidine 6 (H6) and aspartic acid 7 (D7). Familial variants, such as the English variant (H6R) and the Japanese variant (D7N), significantly inhibited this interaction, leading to a reduction in phagocytosis. Furthermore, the paper also elucidates the high-resolution crystal structure of the TREM2-Aβ(1-8) peptide complex, showing the peptide segment bound near the hydrophobic site of TREM2, close to the complementarity-determining region 1 (CDR1). These results not only clarify the key determinants of the interaction between TREM2 and Aβ but also provide a theoretical basis for the development of drugs to treat AD, especially small molecule modulators targeting TREM2 function. In summary, these studies not only define the key interactions that limit AD pathology but also provide a framework for therapeutic targeting of TREM2 to restrict the progression of AD.

Structural and functional analysis of TREM2 interactions with amyloid beta reveal molecular mechanisms that mediate phagocytosis of oligomeric amyloid beta

Amyloid-beta Modulates Microglial Responses by Binding to the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2).

Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer's disease ligands

Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple AD ligands

Deficits in the Mirna-34A-regulated Endogenous TREM2 Phagocytosis Sensor-Receptor in Alzheimer's Disease (AD); an Update.

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2

TREM2 is a Receptor for Β-Amyloid That Mediates Microglial Function

TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease

TREM1 Facilitates Microglial Phagocytosis of Amyloid Beta

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY

The flexible stalk domain of sTREM2 modulates its interactions with phospholipids in the brain

Identification of the Minimal Active Soluble TREM2 Sequence for Modulating Microglial Phenotypes and Amyloid Pathology

TREM2 Ectodomain and Its Soluble Form in Alzheimer’s Disease

TREM2 Regulates Innate Immunity in Alzheimer’s Disease

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

A Tetravalent TREM2 Agonistic Antibody Reduced Amyloid Pathology in a Mouse Model of Alzheimer's Disease.

Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias

Apolipoprotein E is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)*

The Challenges of Modulating Neuroinflammation in Alzheimer's Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice